This Book >>

  • 263pp. Published June 2020
  • Scientific Research Publishing,Inc.,USA
  • Category: Medicine & Healthcare
  • ISBN: 978-1-61896-928-6
  • (Hardcover) USD 109.00
  • ISBN: 978-1-61896-927-9
  • (Paperback) USD 89.00
Authors/Editors Price: 40% off
Buy at:

Connect with SCIRP >>

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
Paper Publishing WeChat
Book Publishing WeChat
Home > Books > Advances in the Treatment of Cardiac Amy...
Advances in the Treatment of Cardiac Amyloidosis
  • Description
  • Author(s) Information
Cardiac amyloidosis is a subcategory of amyloidosis where there is the depositing of the protein amyloid in the cardiac muscle and surrounding tissues. Amyloid, a misfolded and insoluble protein, can become a deposit in the heart’s atria, valves, or ventricles. These deposits can cause thickening of different sections of the heart, leading to decreased cardiac function. The multisystemic disease was often misdiagnosed, with diagnosis previously occurring after death during the autopsy. However, recent advancements of technologies have increased the diagnosis of the disease. This disease has multiple types including light chain, familial, and senile. One of the most studied types is light chain cardiac amyloidosis. The prognosis depends on the extent of the deposits in the body and the type of amyloidosis.
Components of the Book:
  • Chapter 1
    Advances in the Treatment of Cardiac Amyloidosis
  • Chapter 2
    Analysis of autonomic outcomes in APOLLO, a phase III trial of the RNAi therapeutic patisiran in patients with hereditary transthyretin‑mediated amyloidosis
  • Chapter 3
    Bone tissue and mineral metabolism in hereditary endocrine tumors: clinical manifestations and genetic bases
  • Chapter 4
    Cardiovascular magnetic resonance nativeT2 and T2* quantitative values for cardiomyopathies and heart transplantations: a systematic review and meta-analysis
  • Chapter 5
    Diagnosis of Amyloidosis: A Survey of Current Awareness and Clinical Challenges Among Cardiologists in Switzerland
  • Chapter 6
    Dilated cardiomyopathies and non-compaction cardiomyopathy
  • Chapter 7
    DSP p.(Thr2104Glnfs*12) variant presents variably with early onset severe arrhythmias and left ventricular cardiomyopathy
  • Chapter 8
    Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy
  • Chapter 9
    IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome
  • Chapter 10
    Karyomegalic interstitial nephritis with a novel FAN1 gene mutation and concurrent ALECT2 amyloidosis
  • Chapter 11
    Management of life-threatening hemoptysis
  • Chapter 12
    Novel myocardial markers GADD45G and NDUFS5 identified by RNA-sequencing predicts left ventricular reverse remodeling in advanced non-ischemic heart failure: a retrospective cohort study
  • Chapter 13
    Regression of cardiac amyloid load documented by cardiovascular magnetic resonance in a patient with hereditary amyloidosis
  • Chapter 14
    Renal AA amyloidosis leading to early diagnosis and treatment of takayasu arteritis: a case report and review of the literature
  • Chapter 15
    The epidemiology of heart failure in the general Australian community - study of heart failure in the Australian primary carE settin(SHAPE): methods
  • Chapter 16
    Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future
  • Chapter 17
    Therapeutic effect of high‑efficiency online hemodiafiltration for recurrent restless legs syndrome in dialysis patients
  • Chapter 18
    Unveiling ncRNA regulatory axes in atherosclerosis progression
  • Chapter 19
    Urticaria: recommendations from the Italian Society of Allergology, Asthma and Clinical Immunology and the Italian Society of Allergological, Occupational and Environmental Dermatology
Readership: Students, academics, teachers and other people attending or interested in the Treatment of Cardiac Amyloidosis.
comments powered by Disqus